Neuralink
Neuralink makes brain implants that let paralyzed people control computers with thought.
On the record
Checkpoint: Next Neuralink funding round expected to price the company
The call
Neuralink has money, patents, and patients, but Neuracle already reached the commercial finish line it is still running toward.
Neuralink is building computer chips that doctors surgically implant in the brain to help paralyzed people control devices with their thoughts. The company has real advantages: a custom surgical robot, 26 patients with working implants, and many patents that took years to develop. However, a Chinese company called Neuracle already got government approval to sell a similar implant in March 2026, and other well-funded rivals like Synchron and Precision Neuroscience are racing through US approval too. The biggest question is whether Neuralink can actually get US approval and start mass production before its competitors do, or if Musk's ambitious 2026 goals slip like many surgical device timelines have in the past.
Why
01
AI pressure: Merge Labs (OpenAI-backed non-invasive BCI). If AI decoding software becomes the valuable layer, Neuralink's implant risks becoming commodity hardware under someone else's algorithm. Could AI do the core job? Only partly.
02
Bigger players: Neuracle Medical Technology (China). Neuracle's NEO implant won the world's first commercial invasive BCI approval in March 2026, beating Neuralink's still-unapproved FDA pathway. Could a giant copy it? No, they are blocked.
03
What protects it. Deep pockets, 67 patents, 26 implanted patients, and a working surgical robot give Neuralink a real head start even without approval.
What would change this call
Whether Neuralink, Synchron, or Precision Neuroscience secures first US FDA PMA approval for invasive BCI. Shows which company converts trial data into the first legally marketable US product.
Whether Neuralink's Blindsight human trial begins as targeted in 2026. Shows if Neuralink is expanding beyond motor-control implants into new indications on schedule.
Terms of Neuralink's next funding round (expected 2026) versus prior $9B valuation and secondary market prices up to $47B. Shows whether investor confidence is rising or resetting relative to hype.
Whether Neuralink's Blindsight human trial begins as targeted in 2026. Shows if Neuralink is expanding beyond motor-control implants into new indications on schedule.
Terms of Neuralink's next funding round (expected 2026) versus prior $9B valuation and secondary market prices up to $47B. Shows whether investor confidence is rising or resetting relative to hype.
Key numbers
- 26 patients implanted globally
- $650M raised at $9B valuation
- Neuracle NEO gets first commercial BCI approval
Named risks
- No FDA-approved commercial product exists as of mid-2026, leaving revenue and regulatory path unproven.
- Lost first-commercial-approval race to China's Neuracle in March 2026, undercutting first-mover narrative.
- SEC investigation reopened December 2024 over Physicians Committee animal welfare complaints.
- Reported false federal small disadvantaged business claim in an April 2025 SBA filing.
- Large gap between last primary valuation (~$9B, June 2025) and secondary market pricing (up to ~$47B) risks a valuation reset.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Neuracle Medical Technology | losing to | China's NMPA approved Neuracle's NEO for commercial use in March 2026, first-ever for invasive BCI |
| Synchron | contesting | INTENT pivotal trial advancing in 2026 after $200M Series D, Nov 2025 |
| Precision Neuroscience | contesting | Founded by Neuralink co-founder Benjamin Rapoport, pursuing parallel FDA track |
| Paradromics | gaining on | FDA IDE approved Nov 2025, first-in-human procedure completed by June 2026 |
| Apple / Merge Labs (OpenAI-backed) | gaining on | Apple BCI protocol (May 2025) and OpenAI-led $250M Merge Labs bet on non-invasive path |
Questions people ask
- Is Neuralink FDA approved for commercial sale?
- No. As of July 2026 Neuralink has no FDA-approved commercial product; it operates under clinical trials (PRIME, Convoy, VOICE). China's Neuracle beat it to the first-ever commercial invasive BCI approval via NMPA in March 2026.
- Who owns Neuralink?
- Neuralink is privately held and venture-backed. Elon Musk is reported to hold over 50% ownership as of July 2026, with Jared Birchall, head of Musk's family office, serving as CEO.
- Is Neuralink profitable?
- No. As of mid-2026 Neuralink has no FDA-approved product and reports no meaningful verified product revenue; its last confirmed funding was a $650M Series E closed June 2025 at roughly a $9B valuation.
- Could AI replace Neuralink's technology?
- AI could commoditize Neuralink's neural-decoding software layer, but its FDA-regulated implant hardware, R1 surgical robot, 67 patents (as of April 2026), and data from 26 implanted patients require physical deployment AI alone cannot replicate.
- Who is Neuralink's biggest competitor?
- China's Neuracle Medical Technology got the world's first commercial invasive BCI approval in March 2026, ahead of Neuralink. Synchron, Precision Neuroscience, and Paradromics are also racing toward US FDA approval in parallel.
- How many patients has Neuralink implanted its device in?
- Neuralink reached its 26th implanted patient globally by July 15, 2026, across trial sites in the US, UK, Canada, and UAE, up from 21 participants reported in January 2026.
Timeline
- 2026-07-15Neuralink reaches 26th implanted patient globally across US, UK, Canada, UAE
- 2026-05-28Neuralink says next-gen R1 robot can place threads in virtually any brain region
- 2026-03-01China's Neuracle gets world-first commercial NMPA approval for invasive BCI, beating Neuralink
- 2026-02-01Paradromics begins patient recruitment for its Connexus implant trial
- 2026-01-01Neuralink reports 21 participants enrolled across PRIME study sites
- 2025-12-31Musk announces plan for high-volume N1 production with automated surgery in 2026
- 2025-11-01Paradromics receives FDA IDE approval; Synchron closes $200M Series D
- 2025-10-05OpenAI leads $250M investment in non-invasive BCI rival Merge Labs
- 2025-06-01Neuralink closes $650M Series E at roughly $9B valuation
- 2025-05-01Apple announces BCI Human Interface Device input protocol
Revision history
20 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- China beat Neuralink to the first commercial brain implant. Here's what that means. (2026-07-16)
- Neuralink reaches 26th patient in ongoing brain-computer interface trials (2026-07-15)
- Elon Musk says Neuralink brain implants are at 'Jesus level', Neuralink reaches 26th patient (2026-05-21)
- ARK Funds Neuralink Investment Thesis (2026-05-27)
- Neuralink valuation, funding & news (2025-12-02)
- CB Insights Neuralink Financials (2026-05-05)
- Neuralink's Private Market Price, Betting a Future Doesn't Exist (2026-07-12)
- Neuralink pre-IPO investments (2026-07-08)
- Growjo Neuralink Company Profile (2022-04-16)
- Tech Times Neuralink BCI Article (2026-05-28)
- Proactive Investors (2025-11-09)
- Tech Funding News (2024-12-02)